Clinical Decision-Making
CHA2DS2-VASc Score: Stroke Risk and Anticoagulation in Atrial Fibrillation
CHA2DS2-VASc identifies which atrial fibrillation patients need anticoagulation. Score 0 (men) or 1 (women, sex point only) = low risk; no anticoagulation. Score 2+ (men) or 3+ (women) = anticoagulation recommended. DOACs preferred over warfarin in non-valvular AF.
TL;DR: CHA2DS2-VASc identifies which atrial fibrillation patients need anticoagulation. Score 0 (men) or 1 (women, sex point only) = low risk; no anticoagulation. Score 1 (men) or 2 (women) = consider. Score 2+ (men) or 3+ (women) = anticoagulation recommended. The score outperforms its predecessor CHADS2 at identifying truly low-risk patients. In 2025, starting a DOAC in AF is rarely a hard decision — CHA2DS2-VASc makes it structured.
CHA2DS2-VASc Scoring
| Risk Factor | Points |
|---|---|
| Congestive heart failure | 1 |
| Hypertension | 1 |
| Age ≥75 years | 2 |
| Diabetes mellitus | 1 |
| Stroke / TIA / thromboembolism (prior) | 2 |
| Vascular disease (prior MI, PAD, aortic plaque) | 1 |
| Age 65–74 years | 1 |
| Sex category female | 1 |
Score range: 0–9
Score Interpretation
In Men
| CHA2DS2-VASc | Annual Stroke Risk | Recommendation |
|---|---|---|
| 0 | <1% | No anticoagulation |
| 1 | ~1.3% | Consider anticoagulation |
| 2+ | ≥2.2% | Anticoagulation recommended |
In Women
| CHA2DS2-VASc | Recommendation |
|---|---|
| 1 (sex only) | No anticoagulation |
| 2 | Consider anticoagulation |
| 3+ | Anticoagulation recommended |
HAS-BLED: The Bleeding Counterpart
HAS-BLED ≥3 = high bleeding risk. This does NOT mean withhold anticoagulation. It means address modifiable factors.
DOAC Selection Guide
| DOAC | Standard Dose | Reversal Agent |
|---|---|---|
| Apixaban | 5 mg BID | Andexanet alfa |
| Rivaroxaban | 20 mg daily | Andexanet alfa |
| Dabigatran | 150 mg BID | Idarucizumab |
| Edoxaban | 60 mg daily | Andexanet alfa |
Special Populations
- Valvular AF: CHA2DS2-VASc does not apply — anticoagulation is mandatory
- HCM + AF: Anticoagulate regardless of score
- Subclinical AF: Evidence evolving (ARTESIA, NOAH-AFNET 6 trials)
Evidence and Guidelines
- Zhu WG, et al. Tex Heart Inst J. 2015;42(1):6-15. PMID: 25873792.
- Liu FD, et al. Ann Med. 2016;48(5):367-375. PMID: 27153002.
- Lip GYH, et al. Chest. 2010;137(2):263-272. PMID: 19762550.
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS AF Guideline. J Am Coll Cardiol. 2024;83(1):109-279. PMID: 38043043.
References
- Zhu WG, et al. Tex Heart Inst J. 2015;42(1):6-15.
- Liu FD, et al. Ann Med. 2016;48(5):367-375.
- Lip GYH, et al. Chest. 2010;137(2):263-272.
- Joglar JA, et al. J Am Coll Cardiol. 2024;83(1):109-279.